<DOC>
	<DOCNO>NCT00647400</DOCNO>
	<brief_summary>To evaluate efficacy , safety , pharmacokinetics adalimumab Japanese participant psoriasis</brief_summary>
	<brief_title>Adalimumab Adult Japanese Subjects With Psoriasis</brief_title>
	<detailed_description>This continuation trial adalimumab participant moderate severe chronic plaque psoriasis complete Study M04-688 ( NCT00338754 ) , 24-week , double-blind , placebo-controlled study . This study open-label extension study continue approval adalimumab treatment psoriasis Japan . During Study M04-688 ( NCT00338754 ) , participant receive 24 week treatment adalimumab 40 mg every week ( eow ) without load dose , adalimumab 80 mg eow , placebo . At start study , participant receive adalimumab 40 mg eow adalimumab 80 mg eow Study M04-688 ( NCT00338754 ) continue treatment regimen . Participants receive placebo Study M04-688 ( NCT00338754 ) re-randomized start study receive adalimumab 40 mg eow adalimumab 80 mg eow . Participants adalimumab 40 mg eow treatment group fail achieve PASI50 response ( &gt; = 50 % reduction Psoriasis Area Severity Index score Baseline Study M04-688 [ NCT00338754 ] ) anytime Week 12 study give option increase dose adalimumab 80 mg eow . Once dose escalate , option de-escalate dose back 40 mg eow . Participants fail achieve PASI50 response receive adalimumab 80 mg eow may discontinue study evaluate risk/benefit treatment adalimumab . At Week 28 study , mandatory participant start study adalimumab 80 mg eow treatment group ( i.e. , include dose escalator describe ) reduce dose adalimumab 40 mg eow , regardless response status . Following mandatory dose reduction , participant fail achieve maintain PASI50 response , permit escalate dose adalimumab 80 mg eow . There option de-escalate dose back 40 mg eow follow dose escalation . Data clinical trial result disclosure analyze observed accord treatment receive start study ( i.e. , adalimumab 40 mg eow adalimumab 80 mg eow ) regardless subsequent dose escalation . Data summarize accord participant ' cumulative exposure adalimumab Study M04-688 ( NCT00338754 ) study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participants complete Study M04688 ( NCT00338754 ) Participant consider investigator , reason , unsuitable candidate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>